Trial Profile
A Phase II Randomized Study of Oral CC-5013 Lenalidomide (Revlimid), an Antiangiogenic and Immunomodulatory Agent in Subjects With Stage IV Ocular Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Eye neoplasms; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 27 Feb 2012 Planned number of patients changed from 38 to 76 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Planned number of patients changed from 38 to 76 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.